Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants with Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Trial Identifier: 9999-01A
Sponsor: MSD
Start Date: August 2024
Primary Completion Date: March 2029
Study Completion Date: March 2029
Condition: Lymphoma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary – English

Trial Locations

Country Location
Brazil, Sao Paulo São José do Rio Preto, Sao Paulo, Brazil, 15090000
Israel, N/A Haifa, N/A, Israel, 3109601
Israel, N/A Ramat Gan, N/A, Israel, 5265601
Korea, Republic of, Seoul Seoul, Korea, Republic of, 03080
Korea, Republic of, Seoul Seoul, Korea, Republic of, 05505
Spain, Madrid, Comunidad de Madrid, Madrid, Comunidad de, Spain, 28009
Taiwan, Taipei Taipei, Taiwan, 10002
United Kingdom, Cardiff Cardiff, United Kingdom, CF14 4XW
United Kingdom, England Newcastle upon Tyne, England, United Kingdom, NE1 4PL
United Kingdom, London, City of London, London, City of, United Kingdom, NW1 2PG
United States, CT New Haven, CT, United States, 06510
United States, IA Iowa City, IA, United States, 52242
United States, NJ New Brunswick, NJ, United States, 08903
United States, NY Valhalla, NY, United States, 10595
United States, PA Philadelphia, PA, United States, 19104
United States, UT Salt Lake City, UT, United States, 84113